BiotechTube

HAV

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Failure

Conditions

Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis

Trial Timeline

Nov 12, 2019 → Mar 2, 2022

NCT ID
NCT04135417

About HAV

HAV is a phase 2 stage product being developed by Humacyte for Renal Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT04135417. Target conditions include Renal Failure, End Stage Renal Disease, Vascular Access.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04135417Phase 2Completed

Competing Products

20 competing products in Renal Failure

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
AGS-16M8FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23

Other Products from Humacyte

Acellular Tissue Engineered Vessel (ATEV)Phase 3
69
Human Acellular Vessel (HAV)Phase 3
69
Human Acellular Vessel (HAV)Phase 3
69
Human Acellular Vessel (HAV)Phase 2/3
57
Human Acellular Vessel (HAV)Phase 2
44